Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib
Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the
Quality of life and extremity function post-combination treatment; To study the mechanism of
radio-sensitizing effects of Anlotinib Hydrochloride for primary truncal or extremity soft
tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and
local control.